NCT07365059 is a EARLY_PHASE1 clinical trial of GPRC5D CAR-T cell intravenous infusion in Plasma Cell Dyscrasias, sponsored by Qi deng.

Who is sponsoring NCT07365059?

NCT07365059 is sponsored by Qi deng.

What drugs are being tested in NCT07365059?

Interventions in NCT07365059: GPRC5D CAR-T cell intravenous infusion.

What condition does NCT07365059 study?

NCT07365059 studies Plasma Cell Dyscrasias.

Is NCT07365059 still recruiting?

NCT07365059 is currently not yet recruiting. Last updated 26 January 2026.

Last reviewed 2026-01-26 · How we verify

NCT07365059

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of GPRC5D CAR-T Cell Therapy in Relapsed/Refractory Plasma Cell Disorders

Not yet recruiting EARLY_PHASE1 Last updated 26 January 2026

What this trial tests

EARLY_PHASE1 trial testing GPRC5D CAR-T cell intravenous infusion in Plasma Cell Dyscrasias in 18 participants. Not yet recruiting.

Timeline

25 January 2026

Primary endpoint
1 January 2029

1 March 2029

Quick facts

Lead sponsor	Qi deng
Phase	EARLY_PHASE1
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	25 January 2026
Primary completion	1 January 2029
Estimated completion	1 March 2029

Drugs / interventions tested

GPRC5D CAR-T cell intravenous infusion — full drug profile →

Conditions studied

Plasma Cell Dyscrasias — all drugs for Plasma Cell Dyscrasias →

Sponsor

Qi deng — full company profile →

Who can join

Adults 14 to 75, any sex, with Plasma Cell Dyscrasias. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is an open-label, single-arm, dose-escalation and expansion, prospective clinical trial. It enrolls patients with relapsed/refractory plasma cell disorders, administers GPRC5D CAR-T cell therapy, follows up to observe adverse reactions after medication, collects relevant data on treatment efficacy, evaluates the safety and efficacy of CAR-T cells, and simultaneously investigates the cellular kinetic characteristics of CAR-T cells.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Plasma Cell Dyscrasias

Currently open trials in the same condition.

NCT03616483 — The Indiana Myeloma Registry · recruiting

Other Qi deng trials

Trials by the same sponsor.

NCT07383233 — CD19/BAFF-R in Vivo CAR-T Cell Therapy Targeting Relapsed/Refractory B Cell Acute Leukemia/Malignant Lymphoma · Phase 1 · not yet recruiting
NCT07008872 — CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07365059 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Qi deng
Last refreshed: 26 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07365059.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing